RJA
HAE icon

Raymond James & Associates’s Haemonetics HAE Stock Holding History

Raymond James & Associates’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.7M Buy
21,162
+4,211
+25% +$340K ﹤0.01% 2323
2024
Q2 		$1.4M Buy
16,951
+7,979
+89% +$702K ﹤0.01% 2386
2024
Q1 		$766K Sell
8,972
-15,078
-63% -$1.18M ﹤0.01% 2776
2023
Q4 		$2.06M Sell
24,050
-8,751
-27% -$757K ﹤0.01% 2083
2023
Q3 		$2.94M Buy
32,801
+3,421
+12% +$305K ﹤0.01% 1786
2023
Q2 		$2.5M Sell
29,380
-18,745
-39% -$1.58M ﹤0.01% 1914
2023
Q1 		$3.98M Buy
48,125
+31,745
+194% +$2.57M ﹤0.01% 1626
2022
Q4 		$1.29M Buy
16,380
+4,226
+35% +$340K ﹤0.01% 2284
2022
Q3 		$900K Sell
12,154
-17,104
-58% -$1.23M ﹤0.01% 2469
2022
Q2 		$1.91M Sell
29,258
-39,190
-57% -$2.32M ﹤0.01% 2014
2022
Q1 		$4.33M Buy
68,448
+13,791
+25% +$750K ﹤0.01% 1611
2021
Q4 		$2.9M Buy
+54,657
New +$3.33M ﹤0.01% 1909
2021
Q3 		– Sell
-10,295
Closed -$686K – 4180
2021
Q2 		$686K Sell
10,295
-9,240
-47% -$654K ﹤0.01% 2847
2021
Q1 		$2.17M Buy
19,535
+54
+0.3% +$6.68K ﹤0.01% 1955
2020
Q4 		$2.31M Buy
19,481
+1,042
+6% +$112K ﹤0.01% 1805
2020
Q3 		$1.61M Buy
18,439
+14,738
+398% +$1.29M ﹤0.01% 1895
2020
Q2 		$331K Sell
3,701
-6,539
-64% -$660K ﹤0.01% 2860
2020
Q1 		$1.02M Sell
10,240
-28,221
-73% -$3.06M ﹤0.01% 1963
2019
Q4 		$4.42M Sell
38,461
-3,838
-9% -$464K 0.01% 1334
2019
Q3 		$5.34M Buy
42,299
+33,611
+387% +$4.27M 0.01% 1185
2019
Q2 		$1.05M Sell
8,688
-1,427
-14% -$140K ﹤0.01% 2185
2019
Q1 		$885K Sell
10,115
-601
-6% -$54.7K ﹤0.01% 2280
2018
Q4 		$1.07M Buy
10,716
+4,632
+76% +$487K ﹤0.01% 2050
2018
Q3 		$697K Sell
6,084
-1,721
-22% -$178K ﹤0.01% 2479
2018
Q2 		$700K Buy
7,805
+4,345
+126% +$367K ﹤0.01% 2446
2018
Q1 		$253K Buy
+3,460
New +$237K ﹤0.01% 3001

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Raymond James & Associates's HAE Position: Q3 2024 in Review

Raymond James & Associates increased its Haemonetics (HAE) stake by 25% in Q3 2024, buying an estimated $340K and bringing the position to 21,162 shares worth $1.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2323.

Raymond James & Associates first reported a position in HAE in Q1 2018 and has held it in 26 quarters since. The position peaked at $5.34M in Q3 2019. 306 funds tracked by Wall St. Rank hold HAE as of Q3 2024.

  • Raymond James & Associates held 21,162 shares of Haemonetics worth $1.7M as of Q3 2024.
  • Raymond James & Associates bought 4,211 Haemonetics shares in Q3 2024, an estimated $340K.
  • Haemonetics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2323 holding.
  • Raymond James & Associates first reported a position in Haemonetics in Q1 2018 and has held it in 26 quarters since.
  • Raymond James & Associates's Haemonetics position peaked at $5.34M in Q3 2019.
  • 306 funds tracked by Wall St. Rank held Haemonetics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.